265 related articles for article (PubMed ID: 33620750)
1. Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico.
Marquez LK; Fleiz C; Burgos JL; Cepeda JA; McIntosh C; Garfein RS; Kiene SM; Brodine S; Strathdee SA; Martin NK
Addiction; 2021 Oct; 116(10):2734-2745. PubMed ID: 33620750
[TBL] [Abstract][Full Text] [Related]
2. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis.
Marquez LK; Cepeda JA; Bórquez A; Strathdee SA; Gonzalez-Zúñiga PE; Fleiz C; Rafful C; Garfein RS; Kiene SM; Brodine S; Martin NK
Int J Drug Policy; 2021 Feb; 88():102710. PubMed ID: 32165050
[TBL] [Abstract][Full Text] [Related]
3. An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis.
Mafirakureva N; Stone J; Fraser H; Nzomukunda Y; Maina A; Thiong'o AW; Kizito KW; Mucara EWK; González Diaz CI; Musyoki H; Mundia B; Cherutich P; Nyakowa M; Lizcano J; Chhun N; Kurth A; Akiyama MJ; Waruiru W; Bhattacharjee P; Cleland C; Donchuk D; Luhmann N; Loarec A; Maman D; Walker J; Vickerman P
Addiction; 2022 Feb; 117(2):411-424. PubMed ID: 34184794
[TBL] [Abstract][Full Text] [Related]
4. Modelling the contribution of incarceration and public health oriented drug law reform to HCV transmission and elimination among PWID in Tijuana, Mexico.
Saldana CDR; Beletsky L; Borquez A; Kiene SM; Marquez LK; Strathdee SA; Zúñiga ML; Cepeda J; Martin NK
Int J Drug Policy; 2022 Dec; 110():103878. PubMed ID: 36242829
[TBL] [Abstract][Full Text] [Related]
5. Estimating the impact of a police education program on hepatitis C virus transmission and disease burden among people who inject drugs in Tijuana, Mexico: A dynamic modeling analysis.
Rivera Saldana CD; Abramovitz D; Beletsky L; Borquez A; Kiene S; Marquez LK; Patton T; Strathdee S; Zúñiga ML; Martin NK; Cepeda J
Addiction; 2023 Sep; 118(9):1763-1774. PubMed ID: 37039246
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
[TBL] [Abstract][Full Text] [Related]
7. Modelling the impact and cost-effectiveness of non-governmental organizations on HIV and HCV transmission among people who inject drugs in Ukraine.
Stone J; Trickey A; Walker JG; Bivegete S; Semchuk N; Sazonova Y; Varetska O; Altice FL; Saliuk T; Vickerman P
J Int AIDS Soc; 2023 Apr; 26(4):e26073. PubMed ID: 37012669
[TBL] [Abstract][Full Text] [Related]
8. Upscaling prevention, testing and treatment to control hepatitis C as a public health threat in Dar es Salaam, Tanzania: A cost-effectiveness model.
Scott N; Mohamed Z; Rwegasha J; Mbwambo J; Lemoine M; Hellard M
Int J Drug Policy; 2021 Feb; 88():102634. PubMed ID: 31882272
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
Lim AG; Aas CF; Çağlar ES; Vold JH; Fadnes LT; Vickerman P; Johansson KA
Addiction; 2023 Dec; 118(12):2424-2439. PubMed ID: 37515462
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
Mohamed Z; Scott N; Nayagam S; Rwegasha J; Mbwambo J; Thursz MR; Brown AS; Hellard M; Lemoine M
Int J Drug Policy; 2022 Jan; 99():103458. PubMed ID: 34624732
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
[TBL] [Abstract][Full Text] [Related]
12. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
13. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population.
Stevens ER; Nucifora KA; Hagan H; Jordan AE; Uyei J; Khan B; Dombrowski K; des Jarlais D; Braithwaite RS
Clin Infect Dis; 2020 Jun; 70(12):2652-2662. PubMed ID: 31400755
[TBL] [Abstract][Full Text] [Related]
15. Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study.
Lanièce Delaunay C; Klein MB; Godin A; Cox J; Kronfli N; Lebouché B; Doyle C; Maheu-Giroux M
Int J Drug Policy; 2023 Jun; 116():104026. PubMed ID: 37075626
[TBL] [Abstract][Full Text] [Related]
16. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
17. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
Martin NK; Boerekamps A; Hill AM; Rijnders BJA
J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25062. PubMed ID: 29633560
[TBL] [Abstract][Full Text] [Related]
18. Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States.
Zelenev A; Li J; Shea P; Hecht R; Altice FL
Clin Infect Dis; 2021 Mar; 72(5):755-763. PubMed ID: 32060534
[TBL] [Abstract][Full Text] [Related]
19. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
[TBL] [Abstract][Full Text] [Related]
20. Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?
Lanièce Delaunay C; Godin A; Kronfli N; Panagiotoglou D; Cox J; Alary M; Klein MB; Maheu-Giroux M
Int J Drug Policy; 2021 Oct; 96():103343. PubMed ID: 34215459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
